Drug-induced uveitis

Moorthy, Ramana S.; Moorthy, Meena S.; Cunningham, Emmett T.

doi:10.1097/icu.0000000000000530

Cited by 65 publications

(55 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interstitial lung irAEs, such as pneumonitis, happen in approximately 10% of patients taking combination therapy compared to3% in PD-1/CTLA-4 monotherapy, and therefore, need particular attention from a physician to examine respiratory symptoms [ 144 ]. The therapeutic management of patients with grade 1 to 2 interstitial lung irAEs is with oral corticosteroids at 1 mg/kg daily and treatment delay is not effective alone regarding the long half-life of ICIs [ 145 ]. Eye irAEs have been seen in patients taking ICIs.…”

Section: Combination Therapy In Different Cancersmentioning

confidence: 99%

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

Kooshkaki

Derakhshani

Hosseinkhani

et al. 2020

IJMS

View full text Add to dashboard Cite

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have been offered as promising targets for the treatment of cancers. Immune checkpoint inhibitors (ICIs)targeting PD-1, including pembrolizumab and nivolumab, and those targeting its ligand PD-L1, including avelumab, atezolizumab, and durvalumab, and two drugs targeting CTLA-4, including ipilimumab and tremelimumab have been approved for the treatment of several cancers and many others are under investigating in advanced trial phases. ICIs increased antitumor T cells’ responses and showed a key role in reducing the acquired immune system tolerance which is overexpressed by cancer and tumor microenvironment. However, 50% of patients could not benefit from ICIs monotherapy. To overcome this, a combination of ipilimumab and nivolumab is frequently investigated as an approach to improve oncological outcomes. Despite promising results for the combination of ipilimumab and nivolumab, safety concerns slowed down the development of such strategies. Herein, we review data concerning the clinical activity and the adverse events of ipilimumab and nivolumab combination therapy, assessing ongoing clinical trials to identify clinical outlines that may support combination therapy as an effective treatment. To the best of our knowledge, this paper is one of the first studies to evaluate the efficacy and safety of ipilimumab and nivolumab combination therapy in several cancers.

show abstract

Section: Combination Therapy In Different Cancersmentioning

confidence: 99%

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

Kooshkaki

Derakhshani

Hosseinkhani

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…A number of medications; topical (metipranolol, glucocorticosteroids, brimonidine and prostaglandin analogs), periocular, intraocular (cidofovir, anti-VEGF agents [ranibizumab, bevacizumab, aflibercept] and triamcinolone acetonide), systemic (cidofovir, rifabutin, bisphosphonates, sulfonamides, tumor necrosis factor inhibitors [TNF-a], oral fluoroquinolones and diethylacarbamazine) and vaccines (bacille Calmette–Guérin, measles, mumps and rubella, hepatitis B and varicella) have been associated with uveitis. Mechanisms underlying drug-induced uveitis are unclear but it is suggested that both toxic and inflammatory reactions play a role 31,32Other collagen diseases including systemic lupus erythematosus (SLE), scleroderma, relapsing polychondritis, necrotizing vasculitis, granulomatosis with polyangiitis (GPA) (formerly known as Wegener’s disease), rheumatoid arthritis, polyarthritis.…”

Section: Etiology Of Non-infectious Umementioning

confidence: 99%

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Massa

Pipis

Adewoyin

et al. 2019

OPTH

View full text Add to dashboard Cite

Macular edema (ME) is the most common sight-threatening complication in uveitis. The diagnostic and therapeutic management of the uveitic macular edema (UME) might be challenging due to the complex diagnostic workup and the difficulties physicians face to find the underlying cause, and due to its usually recurrent nature and the fact that it can be refractory to conventional treatment. Some of the mild cases can be treated with topical steroids, which can be combined with non-steroid anti-inflammatory drugs. However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.

show abstract

“…The ocular side effects related to ICPI are generally immune-related. Their incidence is approximately 1% [71][72][73] and they usually appear between 6 to 12 weeks after starting ICPI therapy [72]. Ocular side effects have most frequently been reported with anti-CTLA4, and comparatively more frequent with anti-PD1 than with anti-PDL-1 [71].…”

Section: Eyementioning

confidence: 99%

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors

Londoño

Reig

2020

Cancers

View full text Add to dashboard Cite

Immune-oncology is a major breakthrough in cancer treatment and has become the standard of care for a wide variety of solid organ malignancies. Unfortunately, manipulation of the immune system with checkpoint inhibitors may result in an immune-based attack of normal tissues which can lead to treatment discontinuation. These immune-related adverse events (irAEs) are diverse and affect several organs, constituting a new clinical challenge in the management of cancer patients. The complexity of this scenario requires a multidisciplinary approach that allows the early identification, diagnosis and treatment of specific irAE, ruling out other non-related adverse events. Hospital Clinic has a multidisciplinary team seeking to develop a coordinated strategy to facilitate the access of patients with suspected irAEs to specialised care resulting in harmonised management that guarantees the best patient care. The aim of the manuscript was to describe the current evidence on the management of irAEs reflecting a coordinated multidisciplinary approach to face this clinical challenge regardless of the immunotherapy indication.

show abstract

Drug-induced uveitis

Cited by 65 publications

References 187 publications

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials

<p>Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges</p>

Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors

Contact Info

Product

Resources

About